Abstract
Background: STYLE (NCT03123471), a phase 3, double-blind, placebo-controlled study, evaluated efficacy and safety of apremilast 30 mg bid (APR) in patients with moderate to severe plaque psoriasis of the scalp and moderate to severe plaque psoriasis. We report pharmacodynamic effects and association between gene expression and APR clinical response in STYLE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
